BCR and chronic myelogenous leukemia, BCR-ABL1 positive: For the patients with CP-CML with the T315I mutation, MMR was achieved or maintained in five patients (28%) by 12 months regardless of their baseline level of BCR::ABL1IS, although a five-fold dose was required to achieve similar efficacy as in patients without the T315I mutation (18).